Genesis Global Group
Ingenio Diagnostics
GD3

You will now be redirected to the GD3 website

Ingenio Diagnostics is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.

Learn more about GD3
Search

News

Contact our Experts

  • September 1, 2024

    Genesis Drug Discovery & Development to attend Gene Therapy for Ophthalmic Disorders Summit in Boston

  • July 1, 2024

    Genesis Drug Discovery & Development Appoints Madeline Farley, Ph.D. as Chief Scientific Officer of the Biochemistry and Bioanalytical Division

  • June 13, 2024

    Exhibitor at the ASM-Microbe 2024 Conference in Atlanta, GA

    June 13-17

  • May 9, 2024

    Exhibitor at the ARVO 2024 Vision for the Future Conference in Seattle, WA

    May 5-9

  • May 1, 2024

    Genesis Drug Discovery & Development Attends The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle

  • March 10, 2024

    Exhibitor at the Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah

    March 10–14

  • March 1, 2024

    Genesis Drug Discovery & Development Attends Society of Toxicology Annual Meeting in Salt Lake City

  • February 1, 2024

    Genesis Drug Discovery & Development Appoints Anthony Rohr, B.S., LATG, CLSSBB as Director of Business Development

  • July 1, 2023

    Genesis Drug Discovery & Development Appoints Christopher Dillion, B.A., LATG, CPIA as Chief Operating Officer.

  • June 1, 2023

    Genesis Drug Discovery & Development Appoints Madeline Farley, Ph.D., as Managing Member of PharmOptima

  • May 10, 2023

    Genesis Drug Discovery & Development (GD3), a member of Genesis Global Group, acquires JSS Medical Research to expand its clinical services portfolio.

    Read More

  • January 10, 2023

    Genesis Axis Acquires Organochem to Grow the Preclinical Chemistry Services Portfolio.

    Read More

  • October 7, 2021

    Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)

    Read More

  • March 4, 2021

    Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add “off the shelf” PK profiling capabilities to its portfolio

    Read More

  • January 6, 2021

    Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services

    Read More

  • December 9, 2020

    Genesis Biotechnology Group announces second year of CRO relationship with Yale University

    Read More

  • September 16, 2020

    Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development

    Read More

  • September 16, 2020

    Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer

    Read More

  • September 16, 2020

    Genesis Biotechnology Group Appoints Erich E. Dagnal as Director of Mergers & Acquisitions

    Read More

  • August 5, 2020

    Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services

    Read More

  • August 4, 2020

    Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima

    Read More